Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 441.00K | 441.00K | 820.00K | 807.00K | 1.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 441.00K | 441.00K | 820.00K | 807.00K | 1.45M |
| Cost of Revenue | 20.80M | 15.28M | 10.16M | 3.91M | 5.35M |
| Gross Profit | -20.36M | -14.84M | -9.34M | -3.10M | -3.90M |
| SG&A Expenses | 19.59M | 17.24M | 14.68M | 12.89M | 10.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.75M | 41.31M | 32.13M | 23.01M | 21.33M |
| Operating Income | -50.31M | -40.87M | -31.31M | -22.20M | -19.88M |
| Income Before Tax | 73.13M | -35.02M | -7.97M | -36.21M | -142.87M |
| Income Tax Expenses | 115.00K | 114.00K | -9.00K | 13.00K | 13.00K |
| Earnings from Continuing Operations | 73.01 | -35.13 | -7.96 | -36.22 | -142.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.01M | -35.13M | -7.96M | -36.22M | -142.88M |
| EBIT | -50.31M | -40.87M | -31.31M | -22.20M | -19.88M |
| EBITDA | -50.04M | -40.70M | -31.17M | -22.05M | -19.72M |
| EPS Basic | -2.77 | -142.66 | -149.34 | -177.15 | -318.82 |
| Normalized Basic EPS | 2.30 | -65.10 | -66.25 | -85.59 | -176.11 |
| EPS Diluted | -11.38 | -151.27 | -168.06 | -192.06 | -328.93 |
| Normalized Diluted EPS | 1.04 | -66.36 | -67.51 | -85.59 | -176.11 |
| Average Basic Shares Outstanding | 49.68M | 40.02M | 30.60M | 25.25M | 1.92M |
| Average Diluted Shares Outstanding | 54.92M | 45.26M | 35.84M | 25.25M | 1.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |